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ABSTRACT
DETERMINING THE MOST EFFECTIVE WAY IN WHICH TO MANAGE
CONGESTIVE HEART FAILURE PATIENTS
Beatrice Ugiliweneza
November 22,2010
Background: CHF is a chronic disease that affects nearly five million people each year;

in which at least 500,000 are newly diagnosed cases. Patients diagnosed with this disease
will be under a physician's care for the remainder of their life. It is of great importance
that the strategy, used to manage these patients, maximizes their health outcomes in a
cost effective manner.
Objective: The objective of the current analysis is to compare the health outcomes with

the available CHF management methods: the 'Case Management' (CM), the 'Self
Management' (SM) and the current 'Standard of Care' (SC). Also, this study aims to
identify the optimal management programs for CHF patients.
Data: Data used are from a multicenter clinical trial funded by the AHRQ. The trial

enrolled 134 patients randomized to three study arms representing the three management
methods. These participants were followed for 12 months.
Statistical methods: To describe the distributions of the outcome variables, summary

statistics were used. For the inferential statistics, comparisons of means across the study

v

arms were performed usingANOVA techniques and comparisons of proportions were
performed using Logistic Regression models. Survival analysis techniques, Kaplan Meier
curves and Cox Regression, were used to compare the group effect in delaying the timing
until the first hospitalization.

Results: Throughout the trial, the SC arm was represented with better outcomes for all
the outcomes of interest. On average, patients in the SC arm had more hospital free days
(335

± 72), shorter in-hospital length of stay (4 ± 13), fewer hospitalizations (1± 2) and a

longer time delay for first hospitalization (139 ± 118) in comparison to the patients in the
CM and SM arms. However, the differences were not statistically significant (p-value >
0.05).

Conclusion: The results from the current study did not establish if one management
program had significantly better outcomes when compared to the other two.
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CHAPTER I
INTRODUCTION
Background

Congestive Heart Failure (CHF) is a clinical condition characterized by lack of
perfuse systematic circulation due to the heart's damaged pumping capabilities [1,2].
CHF affects nearly 5 million people each year; in which at least 500,000 are newly
diagnosed cases [3]. While it is estimated that 1.5 to 2.0% of all Americans suffer from
CHF, CHF disproportionately affects individuals older than 65 years of age in which the
prevalence is estimated to be 6-10% [3]. In addition, men and African Americans are
more likely to suffer from CHF, when compared to women and whites. Annually, CHF
directly causes 39,000 deaths and is a contributing factor in another 225,000 deaths [4].
CHF is traditionally viewed as a chronic condition that is the result of silent
killers such as hypertension and unmanaged diabetes. However, more recently, clinical
research has focused on CHF cases that occurs suddenly [1]. CHF has always been a
fruitful area of research due to its high rate of mortality and morbidity as well as being
the leading cause of hospitalization in the elderly [5]. As a result, not only does CHF
cause extensive medical burdens for society, CHF also carries a tremendous
financialburden as well. It is estimated that $10 billion are spent annually for the
management ofCHF patients[4].
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Fortunately, some cases ofCHF are curable; such as cases of heart failure that are
most likely caused by either an excessive workload like anemia or thyrotoxicosis (in
which clinicians treat as a primary disease) or those caused by anatomical problems like
valve defect (which require surgical corrections). Although, unfortunately, most forms of
heart failure (those due to damaged heart muscle) have no known cure. The treatments
available, aim to improve the patient's quality oflife as well as their length of survival
[1]. These treatments comprise drug therapy and, more importantly, lifestyle changes by
the patient. The recommended lifestyle changes consist of: quitting smoking (if
applicable), losing weight (if necessary), abstaining from alcoholic beverages, reducing
salt and fat intake, and staying physically active [1]. To manage CHF patients' physician
monitors them closely and routinely follows-up with the patients with appointments
scheduled each 3 to 6 months. This management strategy is the current standard of care
for CHF patients. In addition, patients should monitor their weight by weighing
themselves daily; since weight gain can be a sign that the patient's body is retaining fluid,
which may indicate that their heart failure is worsening.
To assist both patients in their self monitoring as well as clinicians in the
monitoring of the patient, two more contemporary management strategies have recently
been proposed. These two forms of management have been entitled 'Case Management'
and "Self Management'. When Case Management is advocated for a patient, the patients
are given a special scale and transmission machine that allow them to measure and record
their weight and other important parameters specific to them daily in their home. This
system is connected and transmits the data to a call center that is staffed by trained nurses
that monitor the values. If there is a significant change in any measurement's value, then,
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the nurse either in agreement with the physician's office, contacts the patient makes an
appointment for them with their doctor or the nurse advises them to go to the nearest
Emergency Department(ED). When Self Management is advocated for a patient, the
patient is given the same scale as in the Case Management and a 'Smart Box'. The scale
takes the same measurements as those measured in Case Management; however, these
are transmitted to the' Smart Box' itself (which is not connected to a nurse staffed call
center) advises the patient to call the doctor for an appointment or visit the ED when
warranted. Hence, self management does not require any additional personnel. As such,
in order to determine the most optimal way in which to manage CHF patients the effects
of each management strategy must be evaluated simultaneously. Therefore, the study aim
of the current project was to determine the health benefits of using Case Management
and/or Self Management, when compared to the current standard of care.

Congestive Heart Failure (CHF)
Overview
Heart failure is clinically defined when the cardiac pump function is impaired
losing its ability (and elasticity) to meet the body's metabolic[2]. While congestion, (the
buildup of fluid in one's body) is common in CHF patients, it is not present in all CHF
patients. The term heart failure does not mean that the heart has stopped working; it
signifies that the heart is failing. That the heart's ability to pump adequate amounts of
blood to fully oxygenate the body is weakened and that the heart is working less
effectively. Regrettably, in most cases this is incurable without surgical repairs or a
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transplant. When surgery or transplantation is unreasonable, prolonging life is the goal of
management.
The severity of the disease is defined by the level of the pumping capacity loss
and indicates the impact the disease will have on the patient's quality and quantity oflife.
Usually, treatment helps patients live complete and fulfilling lives and extends the time
between two critical conditions: the mild form that has little impact on the patient's life
and the severe form that can interfere with even very simple activities [1].

TypesojCHF
Classically, CHF is classified in two main categories ofCHF according to the
elasticity condition of the heart:
•

Systolic heart failure: In this condition, the heart has a problem to contract and

forcing the blood out of the heart. The heart loses its ability to push a sufficient
amount of blood into the circulation. Therefore, the cells of the body are not fully
oxygenated and will begin to die.
•

Diastolic heart failure: In this condition, the heart has a problem relaxing. The

heart loses its ability to fill with blood because the muscle has become stiff [1].
Therefore even if the heart could contract properly, there would not be enough
blood to force out of the heart.
More recently, the types of CHF heart failure are determined by the Ejection Fraction
(EF) of the left ventricle. The EF is the fraction of blood (in percentage) ejected by the
left ventricle during the contraction phase of the cardiac cycle. This EF qualifies the
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functionality ofthe left ventricle. The normal value is 58% and when it found to be less
than 35% then, the left ventricle function (L VF) is said to be depressed. Thus, there are
two main types of heart failure (HF):
•

HF without preserved L VF: In this case, the ventricle is depressed; it cannot

contract to eject enough blood.
•

HF with preserved LVF: The ejection fraction is good (EF > 35) but, the ventricle

has difficulties to expand and relax to receive enough blood.

Treatment of CHF
Since most forms of CHF forms are incurable, treatment is routinely focused on
prolonging life and increasing a patient's quality of life. Patients must carefully monitor
themselves to minimize the effect of CHF by controlling their risk factors for general
heart disease. This potentially can be achieved by the patient incorporating an appropriate
lifestyle. In addition to this, the patient must be closely monitored by a doctor through
follow-up appointments. Furthermore, a majority of heart failure patients have to take
medications to help the heart in its ability to pump.
The most common medications taken by CHF patients are:
•

ACE (angiotensin converting enzyme) inhibitors to help open up vessels and help
the heart not work very hard.

•

Diuretics to help the body get rid of fluid and salt.

•

Digitalis glycosides to help the heart contract.

•

Angiotensin receptor blockers (ARBs) to reduce the workload of the heart.
5
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Beta-blockers which is particularly useful for those who have had a coronary
artery disease.

Some patients who suffer from the more severe forms of CHF require the
implantation of devices such as IABPs (Intra-aortic balloon pumps) or LV ADs (Left
Ventricular assist devices) to assist with their management. These devices are usually a
temporary solution that bridges the patient to a heart transplant [1].
Target population
It is well established that the risk of CHF increases with age. Thus, the condition

is mostly prevalent in older individuals. It affects about 1% of people age 50, but about
5% people age 75 [1]. The disease affects more men than women and is twice prevalent
in African Americans than in whites [1].
The problem

CHF is a chronic disease that affects a considerable proportion of the population
in the US, especially older individuals. The incidence of the CHF disease is positively
correlated with age increasing dramatically for each year of age over 50. The inpatient
and outpatient costs associated with CHF are estimated to be in the tens of billions of
dollars each year in the US. Similarly, the prevalence ofCHF continues to increase as the
baby boomers continues to age. As a result, CHF will continue to increase as a burden for
society [6]; therefore there is an urgent need to establish effective ways in which to
manage CHF patients. That is, there is a need to address the management of CHF in a
way that considers the medical effectiveness for the patient.

6

Purpose of the current study
The main goal of this study was to compare the three management methods, the
smart-box self monitoring (Self Management), the tele-monitoring with a nurse-staffed
call center (Case Management) and the current standard of care; in terms of hospital free
days, hospital admission rates and in delaying the timing until the first hospitalization
managing CHF patients with either.
Data used are from a multi-center clinical trial, funded by the Agency of
Healthcare Research and Quality (AHRQ), which enrolled 134 congestive heart failure
patients. These participants were randomly assigned to the three management strategy:
Standard Care was the first arm, Case Management was the second arm and Self
Management was the third arm. All the physicians following the participants in this
clinical trial were given the American Heart Association!American College of Cardiology
(AHA/ACC) guidelines. Patients were followed for 12 months and the primary endpoints
were Emergency Department (ED) visits and hospital readmissions.
Description of study arms
Standard Care

For patients who were enrolled in the standard care management arm, they
remained under the care of their usual physician, who could be a cardiologist or a regular
family doctor, with regular appointments scheduled every 3 to 6 months to monitor their
health [1]. In addition to these visits, the patients were encouraged to develop a healthier
and more appropriate lifestyle, track their weight and comply with prescribed
medications.
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Case Management
For patients in the case management arm, they were also followed by a doctor
similarly as those in the standard management arm. Additionally, these individuals were
provided with a scale and modem machine connected to a nurse staffed call center
through the email via the phone. For each patient, this scale was programmed to ask the
individual, once on the scale every morning, questions related to their condition. These
questions were prepared by the physician in charge of the participant and they were
tailored to their specific type and level ofCHF disease. The patients' weights as well as
their responses were immediately sent via the internet to the nurse staffed center. This
center had a list of normal parameters, tailored the physician to each patient, to which
they compared the responses. If there was an alert, the nurse would contact the
physician's office or recommend seeking an immediate medical treatment at the nearest
Emergency Department (ED).

Self Management
For patients in the self management arm, they are followed by a doctor regularly
(similar as above). However, instead of a machine connected to a nurse staffed call
center, the patients were provided with an automated smart box, connected through a
modem and the internet, immediately to the physician'S office. This smart box was
programmed and tailored to each patient with a list of normal ranges of important CHF
parameters. Just like in the Case Management arm, patients were given a scale with a set
of questions adapted and specific to them. But, here, the responses were transmitted to
the smart box which would then, perform the necessary comparisons. If there was a
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significant change, an alert was sent to the physician's office or the box would advice the
patient to go to the nearest ED.
Study overview
The current study investigated the effectiveness of each one of the management
strategies considered for managing CHF patients. Initially a descriptive statistical
analysis was performed to look at the population involved. Then, an inferential analysis
was performed to test for differences in the outcomes studied between the three
management strategies.
In addition to the traditional statistical analyses, a survival analysis was done to
evaluate the difference in the time until the first hospital admission.
Implications from the Study
The current analysis will permit health care providers and their patients to see the
advantages and disadvantages of each strategy and will assist them when deciding how to
optimally manage their CHF.
Summary of the whole study
Congestive Heart Failure is a chronic disease which has an increasing incidence in
the United States. The health outcomes of its management are important issues that must
be addressed in order to provide care for CHF patients effectively. Three management
strategies currently being evaluated for their medical soundness were considered in the
current study: the standard care, the case management and the self management strategy.
The objective of this study was to estimate the health benefits of managing CHF patients
9

with either self management or case management when compared to the current standard
of care.
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CHAPTER II
LITTERATURE REVIEW

Overview
Congestive Heart Failure (CHF) also referred to simply as Heart Failure (HF) is a
condition in which the heart cannot pump enough blood to adequately supply the rest of
the body [1]. Most of the time, CHF is the result of the myocardial failure that has
affected either the left or the right ventricle or sometimes both ventricles [1,3]. CHF is an
irreversible condition that often causes symptoms that make everyday life very difficult.
In addition, unfortunately, currently, there is no cure for the disease. Patients diagnosed
with CHF can only improve their lives by adhering to appropriate healthy life changes
and by complying with medications.
The incidence and prevalence of CHF are high in the United States, especially in
the population age 65 and over. The incidence and prevalence of CHF are most likely to
continue to increase due to the increase in baby-boomers reaching 65 years of age.
Patients with CHF have a very high rate of hospitalizations and readmissions to the
hospital, which translates to high costs, associating CHF with high health expenditure.
The fact that it is an incurable disease implies that the condition of CHF patients worsen
over time. Although treatments and management strategies have improved considerably
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in the past years, CHF is still associated with a high mortality rates and many detriment
morbidities.
Most of the time, CHF causes significant reduction of physical health which is
linked to a very poor quality of life for the patients. Thus, family and social support play
an important role in the patients' lives.
Many efforts have been made to help improve not only the patients' conditions
but also to and reduce the burden on society. To help patients cope with their condition,
reduce hospitalizations and prolong survival (life expectancy), a new management
strategy has been proposed; the nurse management program. These nurse management
strategies traditionally assign a patient to a nurse for regular tailored communication and
contact -thru personal, telephonic and even advanced technology contacts. The medical
effectiveness as well as and the cost effectiveness of these methods have been widely
discussed in the medical literature. However, the conclusions are variable and are contrast
with one another. Some results are favorable, while others are unfavorable.

History of Congestive Heart Failure
As early as the 16th _18 th century, from the connoisseurs' writings such as William
Harvey (1578-1657) and Lazare Riviere (1989-1655) and others, recognize and describe
anomalies and diseases people died of very similar to heart failure. At that time, these
disorders were referred to as 'abnormal physiology'. Around the end of the 18th century
and in the 19th century, texts of the time described conditions analogous to heart failure as
'concentric and eccentric hypertrophy (architectural anatomy),. In the early 20th century,
the diseases with symptoms like heart failure were viewed as 'rheumatic heart disease'
12

and they represented approximately 60 to 80% of all adult heart diseases. It was not until
the 1950's that the condition was named the 'failing heart' condition which eventually
evolved to be called 'Heart Failure' as it is known today.
For many years, the advocated treatment of Heart Failure had been prolonged bed
rest. Half a century ago, some specific medications such as diuretics were introduced for
the treatment of congestive heart failure. Later, in the 1970s,

~-adrenergic

agonists and

phosphodiesterase inhibitors started to be used to combat symptoms of CHF. In the
1990s, new drugs known as vasodilators as well as

~-adrenergic

were added to the

advocated list of medications for congestive heart failure [7]. Other treatment options that
have been developed in the last couple of decades include surgery and use of medical
devices.
Epidemiology
Incidence

There are more than 500,000 cases of heart failure diagnosed each year [8, 9],
which is disproportionately diagnosed in elderly populations (65 and older) with an
incidence of about 10/1000 [10]. According to recent studies, for the last 30 years, the
increase in the incidence of Heart Failure has not been dramatic [8]. While the famous
longitudinal Framingham Heart Study showed that there was a significant decrease from
1950 to 1969: no significant change was observed from 1970 [8].
Prevalence
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The stability of the Heart Failure incidence is well established, and since DHF is
significantly positive correlated with age, as the aging population increases, the
prevalence of the disease continues and has become very high. Currently more than 5
million, or 2% of the current population, live with a heart failure [8,9]. This is a dramatic
increase compared to the 1971 where the estimate population with heart failure was only
one to two million or 0.5%-1 % ofthe population. An estimated 100%-300% increase in
the prevalence ofCHF. Similar to the incidence ofCHF, Congestive Heart Failure
disproportionately affects is mainly present in the elderly populations. CHF is the only
major cardiovascular disorder that is increasing in prevalence [9].

Congestive Heart Failure in special populations
While Congestive Heart Failure affects both men and women and the symptoms
are similar; the incidence is greater among men [8].
Older people, 65 years of age and older are affected more by this condition [8]. It
is well established that Congestive heart failure incidence increases with age. The
Rotterdham study showed that the incidence is less than 1% in people ages 55 to 64 but it
is more than 17% in the people aged 85 and older [9].
Some population-based studies have shown that Congestive Heart Failure
mortality rate is higher among African American patients compared with white patients
under the age of 65 [8].

Hospitalizations and hospital readmissions
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The Congestive Heart Failure condition is characterized by frequent
hospitalizations. From the U.S. National Hospital Discharge Survey, there has been a
relative increase of 289% from 1979 to 1999 [8] of Heart Failure-related hospitalizations
and the numbers continued to rise during the 1990s [9] and it is anticipated that these
numbers will continue to rise. In 1995, of the 9.4 million Medicare beneficiaries (65 +)
hospitalized, more than 605,000 had Heart Failure [11].
For CHF patients hospitalized, readmission rates are very high. The 30-day
readmission rates are up to 14% and the 60-day readmission rates are greater than 40%. A
study done with the National Medicare data showed that there was an increase in the odds
of hospital readmission at 30-day form 1993 to 1999. In 1995, in the population age 65
and over, the two-day readmission rates were 21.4 per 1000 and the 30-day readmission
rate was a high 208.4 per 1000 [11].

Mortality
The American Heart Association (AHA) has estimated that about 50,000 patients
die of Heart Failure annually. The mortality rate of this condition is high; the one-year
mortality rate is estimated to be about 20% [10]. Regrettably, it is estimated that more
than one half of the patients diagnosed today with CHF will die within the next five years
[12].

Impact of Congestive Heart Failure on the society
Congestive Heart Failure has enormous consequences on the patients' health as
well as the associated costs [8]. As a result, CHF is considered one of the important
public health problems in the United States [9] not only because of its medical burden but
15

also for its economic burden. The total health care expenditure associated with Heart .
Failure was $26.7 in 2004[12] and in 2005. The National Heart, Lung, and Blood institute
estimates that the total Heart Failure-related hospitalization costs ':Vill be close to $15
billion[8]. In 2006, the Heart Failure related total costs were estimated to be 29.6 billion
[13]. The expenses related to Heart Failure were estimated to reach $33.2 billion in 2007
[12]. As clearly seen, these costs have an increasing trend over time and are estimated to
continue to rise.

Risk factors and prevention
Heart Failure is a final pathway of many cardiovascular disorders [8, 14]. The
main risk factors are Coronary Artery Disease (CAD) and hypertension [8].
Since Congestive Heart Failure is a non-curable disease, the emphasis must put on
the prevention. In general, prevention of CHF includes prevention of the main risk factors
(CAD and hypertension), diabetes and ischemic heart diseases [8]. Folsom et al. showed
in their study that having at least one of the four risk factors (blood pressure, plasma
cholesterol, diabetes, and smoking) accounted for 77.1 % of all heart failure events seen.
Therefore, it is important for clinicians to promote the maintenance of a life which avoids
the development of these risk factors [10].

Treatment of Congestive Heart Failure
CHF is a chronic disease that imposes on the patient to adhere to therapeutic
treatment for the remainder of life [15]. In the recent decades, promising new therapies
have been developed. In general, treatment options are aimed to improve symptoms, help
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the heart to pump and in overall, improve the quality of life. These options include drugs,
surgery and medical devices.
Medications developed to treat Heart Failure have the ability to help the patient
function more effectively and attempt to maintain their normal daily living. Therefore,
adherence and compliance to medication can lead to better health outcomes for many
CHF patients. Wu et al. in their study found that Heart Failure patients whose adherence
to medication is less than 88%, had a Hazard Ratio (HR) to first event (ED visit for HF
exacerbation, cardiac hospital readmission, or all-cause mortality) of2.2 by dose count
(p=O.021) and 3.2 by dose-day (p=O.002) [16]. Also, they showed that about one half to
two thirds of Heart Failure related hospitalizations could be prevented by better
adherence medication regiment.
Surgery treatment is administered to patients who are candidates for heart
transplantation. However, there is an issue with ofthe limited availability ofthe donor
hearts [12] and many patients die while waiting for a heart. In this perspective, new
therapies that attempt to try repair the heart such as stem cells for the heart, also known as
cardiac cell therapy, have been developed and are being researched for their
effectiveness.
Many medical devices have developed and are being used to assist the heart to be
more effective and supply the body with enough blood for functioning. They have been
proven to decrease the risk of Heart Failure related events [17] such as hospitalizations,
hospital readmissions and all cause mortality [14].
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Exercise training has been associated with improved outcomes in CHF patients.
Although, rest was routinely the golden rule for Heart Failure patients, many recent
studies have shown that physical training is linked to improved survival and decreased
hospitalizations and that the absence of exercise may lead to worsening of the symptoms
[14].
Despite all these existing treatment options, the primary emphasis remains to be
disease management. Patients diagnosed with CHF have to follow a healthy lifestyle that
mostly comprises of reducing salt intake, eating more fruits and vegetables, exercising
regularly, reducing their weight, quitting smoking and more steps that are tailored to the
individual patient [8]. They have to self monitor themselves through frequent weigh
measurement and comply with medication (on time and with the right dose). Disease
Management is a strategy by which the patients may be assisted in these everyday Heart
Failure-related routines.

Nurse-Administered Disease Management of Congestive Heart Failure
Nurse-Administered strategies were developed to provide Congestive Heart
Failure patients with a nurse, who will help with daily self-monitoring, make a
connection between the patient and the primary care provider, promote compliance to
medication and sometimes provide additional disease management education to the
patient. In these programs, nurses can assist the patient in various ways: they can do
regular visitations; they can communicate with patients by telephone [18] and even by
more advanced technologies where the patient contacts the nurse through a screen
connected to the nurse center 2417.
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There have been several controlled clinical trials conducted to examine the
effectiveness of the Nurse-Administered disease management in different settings.

In most of the trials, patients were assigned to different arms where the control
arm would receive the usual care without any enhancement and the treatment arm would
be appointed a nurse to supplement their usual care.

In a considerable randomized clinical trial the treatment group was assigned
scheduled telephone calls and/or home visits by trained nurses; Dunagan et al. found that
this management program, in a population selected from Barnes Jewish Hospital, St
Louis, MO; delayed hospitalizations, hospital readmissions and Heart Failure-specific
readmission in patients in the treatment group compared to the control. The Hazard Ratio
(HR) and the 95% confidence interval (CI) for the three health care outcomes were
HR=0.67 95% CI = (0.47, 0.96) and p-value=.045, HR= 0.67 95% CI= (0.46, 0.99) and
p-value=.045; and a HR=0.62 95% CI = (0.38, 1.03) and p-value=.063, respectively [18].
Smith et al. showed that, in community-dwelling patients 18 and older in South Texas, on
the treatment arm, this intervention has a positive effect (improvement) on self-reported
health at 6 months (p-value=.04) and 12 months (p-value=.004) [19]. Both these studies
reported a positive impact of the nurse enhance strategy on the management of Heart
Failure. Sisk et aI., in a minority community of Harlem, NY; found that at 12 months,
compared to the control arm, the patients in the intervention arm had fewer
hospitalizations (adjusted difference, -13 hospitalizations/person year; 95% Confidence
interval, (-0.25, -0.001) and better functioning [20].
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However, not all clinical trials coincided with these findings. Weinberger et aI.,
in patients hospitalized with diagnosis of Congestive Heart Failure in nine Veterans
Affairs medical centers, concluded a contrary result in his research. In his study, not only
did this strategy not improve self-reported health status but it also increased the number
of hospitalizations. At the six months follow-up, patients in the treatment group were
hospitalized on average 1.5 ± 2.0 when the patient in the same trial as Weinberger et aI.,
resulted in this line. The patients in the treatment group, compared to the control group,
had higher rates of hospital readmissions (0.19 vs.0.14 per month, p-value=0.005), longer
hospital length of stay (l0.2 vs. 8.8, p-value=0.041); although the quality oflife scores
did not differ (p-value=0.53) [21].
Some researchers could not conclude that the strategy has any impact on the
outcomes. DeBusk et al. [22], in five northern California hospitals, found similar rate of
hospitalization (Proportional hazard= 0.85, 95% confidence interval = (0.45, 1.57)) as
well as similar rate of hospital readmission in both groups (Proportional hazard= 0.98,
95% confidence interval = (0.76, 1.27)). Also, Laramee et aI., in a more heterogeneous
setting, found that the 90-day readmissions rates were the same in both groups (37%)
[23].
Different types of settings of clinical trials have been conducted. Feldman et ai.
conducted a clinical trial in which instead of assigning patients the two arms, nurses were
randomly assigned to .control or to treatment groups. Nurses were supplied information of
different degree. Patients were then assigned to these nurses (not randomly though).
There was also the usual care group: patients with no nurse. The study concluded that
both intervention groups had better mean KCCQ (Kansas City Cardiomyopathy
20

---

-----------------

Questionnaire) score (15.3 and 12.9% respectively) compared to usual care (p-value ~
0.05). Riegel et al. conducted a different type of trial where the primary physicians were
the ones to be randomly assigned to intervention or control. Then, patients were assigned
to physicians (in a non random manner). This research found that at 3 months, Heart
Failure-related hospitalizations in the intervention group were lowered 45.7%. At 6
months, the Heart Failure-related hospitalizations were lowered 47.8%, Heart Failure
days were lowered (p-value=.03) as well as multiple readmissions (p-value=.OI).
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CHAPTER III
METHODS
Overview

Individuals with CHF are subject to continuous management once they receive a
diagnosis of CHF. The treatment therapies available are to control the symptoms, reduce
the negative effects encountered and in general help the patient live as normal a life as
possible. These treatments comprise of medications and regular surveillance by a
physician thru routinely scheduled appointments. Primarily, CHF patients have to adhere
to healthier lifestyles and monitor themselves daily for any change, especially weight
change; since a weight gain may indicate water retention which is associated with a
deterioration of their CHF disease. This type of monitoring is the usual care for CHF
patients and was represented by the 'Standard care' arm in this analysis. Recently, there
have been proposed new strategies for managing CHF patients, which introduce a link
between the patients and their physician during the time between their routinely
scheduled appointments. It is hypothesized that this link will help the patients in their
daily routine of self check up and medication compliance, and will help the doctor to
detect early signs of sickness aggravation/progression. The first form of connection was
to provide a nurse who would regularly interact with the patient and report to the
supervision of the patient's doctor. This was represented by the 'Case Management' in
the current study. The other type of connection, relatively new with respect to the nurse
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management is the use of a 'smart box' which replaces the nurse and hence, reduces the
expenditures related to a nurse's services. This was defined as the 'Self Management'
arm in this analysis.
The goal of this thesis was to identify the most optimal management strategy in
which to manage patients suffering from CHF. To realize this goal, initially differences
between the three groups discussed above (self-management, case management, and
current standard of care) were tested using traditional ANOV A and logistic regression
techniques. Then differences in the time until a patient's first hospitalization were
investigated using survival analysis techniques. In addition, a cost effectiveness analysis
was performed to evaluate the incremental cost effectiveness of the smart-box self
monitoring (Self Management) and the tele-monitoring with a nurse-staffed call center
(Case Management), when compared to the current standard of care. Data and
information used were collected from a randomized clinical trial, funded by the Agency
of Healthcare Research and Quality (AHRQ), which aimed to evaluate the medical
soundness of self management and case management in terms of decreasing emergency
department visits and inpatient hospital readmissions for CHF patients. The trial used a
prospective, experimental design and followed individuals for 12 months.
The database developed subsequent to the clinical trial was stored as an ACCESS
file and exported to SAS for data management and statistical analysis. Data in the final
database included demographics and traditional risk factors, emergency department and
hospital visits, medications, and type of Congestive Heart Failure. A more detailed
description of these data is given below. Only patients with CHF were recruited and
enrolled in the study. The trial was conducted as a multicenter clinical trial with the
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following contributing sites enrolling patients: Billings, MT; Philadelphia, P A;
Louisville, KY; Indianapolis, IN; Lancaster, and New York, NY. The data were deidentified. That is, each patient was assigned a unique, random study identification
number. As a result, the analyst was blinded to patient identification. An independent
data and safety monitoring board monitored the trial for abnormal rates of adverse events
and whether the ,trail could be terminated early. The trial received approval from all
contributing sites Institutional Review Boards (IRBs) to ensure patient safety. Informed
consent was obtained for all participants enrolled in the study prior to participation in the
study and collection of data.
Database Description
The original data sets were developed as a result of the multicenter randomized
clinical trial discussed above. The study enrolled a total number of 134 people. During
the trial each patient was randomly assigned to one of three arms: Standard Care, Case
Management and Self Management. All the participating physicians were given the
AHA/ACC guidelines ofCHF.
In the Standard Care arm, patients received the recommended standard of care,
which included regularly scheduled appointments with their Primary Care Provider
(PCP). The PCP was the patient's usual physician who was not restricted to be a
cardiologist. In addition, patients receiving the standard of care monitored themselves
through a defined protocol (e.g., daily weight measurement, routine blood pressure and
pulse assessment) and if these measurements were abnormal they were advised to
schedule an appointment with their PCP or visit an emergency department if warranted.
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In the Case Management arm, in addition to their regularly scheduled
appointments with their PCP, their routine self monitoring was enhanced by a special
scale that was connected directly to a nurse staffed call center with trained nurses through
the internet. After measuring the weight, the scale was programmed to ask the patients a
list of questions tailored to their condition. At, the nurse staffed center, the weight and the
responses were compared to a set of normal parameters defined by the physician for the
patient. If there was a significant change in the weight or an alert from the responses, the
nurse notified their PCP and a decision for the patient to schedule an appointment or to
go the hospital was made by the PCP or the nurse advised the patient to go to an
Emergency Department.
In the Self Management arm, the patients were given a scale and a automate
smart-box to use for self-monitoring of their measurements (weight and specific CHF
parameters). The scale recorded the weight and the responses and compared them to the
in-programmed normal ranges. Ifthe physician needed to be notified an automated
message was sent to the physician's office. If the patient needed to go to an Emergency
Department, the patient received an alert to seek treatment at the nearest Emergency
Department.
Data was collected on each patient for a total period of 12 months follow-up. The
first nine months were considered to be the active clinical study period and the last three
months were considered a wash out period.
The complete merged data set available for analysis comprised of 15 subsets of
data. However, for the current analysis, four subsets of data were considered: the
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Hospitalization set [admission dates, length of stay in hospital, physical measurements
while in the hospital], the Heart Failure history set [study ID number, NYHA class type,
type of insurance, CHF related diseases and co-morbidities], the Patient Identifiers set
[date of birth, demographics, clinical trial related information such as date the Inform
Consent was signed, the date of enrollment in the study, study arm], and the Visits set
[date of visit, reason of visit, whether the visit is a routine or not, physical measurements
at the time of visit]. The unique subject ID for each patient was consistent across each
subset of data allowing for easy merging of the subsets of data. The final database used
for all analysis, described below, was comprised of these four data sets.

Descriptive Statistical Analysis
To evaluate the distribution of the outcome variables, continuous variables were
summarized as means and standard deviations, while categorical data were summarized
as frequencies. Continuous variables analyzed included age and BMI. Categorical
variables included study arm, age group, race, gender, marital status, living situation (i.e.
alone, not alone), education level, whether the patient was obese, had hypertension,
diabetes type I or type II, hypercholesterolemia, hyperlipidemia, medication type (ACE
[Angiotensin-converting enzyme] inhibitors, Beta Blocker, ~ l-Adrenoreceptor (AR)
Blocker, ACE inhibitor or AR Blocker), type ofCHF (systolic or diastolic CHF, the
NYHA class, whether the patient is NYHA class III or IV, smoking status (current
smoker, not a current smoker), whether the individual was loss to follow up and
mortality.
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Software: Both the descriptive analysis as well as the inferential analyses were performed
in SAS (Statistical Analysis Software) version 9.2.

Inferential statistical analysis
ANOV A and Logistic regression analysis
Comparisons of means across the study arms were performed using ANOVA
techniques and comparisons of proportions were performed using logistic regression.
One-way ANOVA was used to simultaneously compare the three group means from the
independent samples from each study arm. This method assumes that the samples are
independent and have equal variances. For this reason, tests to validate these assumptions
were carried out with the Kernel Density estimation graphs.
Logistic regression models were developed to simultaneously compare the three
group proportions and effect from the independent samples from each study arm.

Variables: For the inferential statistical analysis, the following outcome variables were
considered: 1) In-hospital days, 2) Hospitalfree days, 3) Length of stay, 4) Number of

hospitalizations, and 5) Whether a patient was hospitalized at least once or not and.
In hospital days: Concurrent with the clinical trial, details about an individual's hospital
length of stay were recorded. As such, the total number of days each patient spent at the
hospital during the 365 days of the trail was summed.

Hospitalfree days: Hospital free days were computed by taking the difference of the
number of days a patient spent in the study and subtracting the number of days they were
in the hospital.
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Length ofstay: The length of stay was computed as the difference of the discharge date
and the admission date at the each visit. The average length of stay was used as the
analysis variable.
Number of hospitalizations: The actual numbers oftimes each patient was hospitalized or
went to the ER were counted using admissions data.
Whether a patient was hospitalized at least once or not: This variable was defined to take
the value 1 if a patient had been hospitalized at least once and 0 if the patient had not
been hospitalized during the 365 days of study.
Study arm: The study arm had three values. It was 1 if the patient was randomized in the
'Standard care" arm, 2 if the patient was randomized to the 'Case management' arm and
3 if the patient was randomized to 'Self management' arm.
The adjusted variables: Since there was a considerable amount of data missing due to
loss of follow up, for the first three variables we created adjusted variables (adjusted in
hospital days adjusted hospital free days and adjusted number of times hospitalized). That
is, we let X represent the outcome of interest, the corresponding adjusted variable was
computed the following way: Adjusted X = X

* (365/ in study days), where 365

represented the total length of the study and in study days represented the total number of
days a patient actually stayed in the study. Here, an exit to the study before the end (365
days) was either death or considered to be a loss to follow up.
Survival analysis
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Survival analysis techniques were used to determine and compare the group effect
in delaying the timing until the first hospitalization. The Kaplan Meier curves were
graphed to evaluate the any presence of differences across arms in delaying the first
hospitalization, while the Log rank test was performed to formally test for differences.
Then, Cox regression analysis was used to test the differences and measure the arm effect
on time delay to first hospitalization.

The event of interest: The event of interest in this analysis was the first hospitalization or
ER visit (an ER visit was considered to be a one day hospitalization). If a patient had
been hospitalized at least once, then the first admission to the hospital established the
time the event of interest occurred. If a patient had not been hospitalized then he/she was
considered right censored either due to loss to follow up, to death or the end of the study.

The variables- time and censoring :The time was measured as: (1) the number of days
between enrollment day and the first hospitalization if the patient had been hospitalized at
least once in the study, (2) if the patient had not been hospitalized and was lost to follow
up, then the time was the difference in days of the lost-to-follow-up date and the
enrollment date, and (3) if a patient had not been hospitalized and was in the study until
the last day, the time was the total number of days patients were followed in the clinical
trial.
The censoring variable was represented by delta (l or 0); delta = 1 if the person
had experienced the event and 0 if not. Thus, if a person had been hospitalized at least
once, delta=1. If the patient had not been hospitalized, then delta=O.

Software: For the survival analysis, the SAS package version 9.2 was used.
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Research questions and methods
The research questions and the methods are summarized used in this study are
summarized in the table below.
Table 3.1: Research questions and methods
Research question
Do the hospital free days
differ in the 3 study arms?
Do the hospital free days
differ in the 3 study arms
considering the number of
days in the study?
Does the in hospital days
differ in the 3 study arms?
Does the in hospital days
differ in the 3 study arms
considering the number of
days in the study?
Does the average length of
stay differ in the 3 study?
Does the number of times
hospitalized differ in the 3
study arms?
Does the number of times
hospitalized differ in the 3
study arms considering the
number of days in the
study?
Does the study arm have an
effect on the
hospitalization usage?
Are the hazards of being
hospitalized the same in
the 3 study arms?
Does Case Management or
Self Management have a
different effect than
Standard Care?
Is any management system
other than Standard Care
has a different effect?

Outcome
Number of hospital free
days

Independent
variable

Statistical
analysis
ANOVA

Study arm

Adjusted number of
hospital free days

Study arm

Number of in-hospital
days

Study arm

ANOVA

Adjusted number of inhospital days

Study arm

ANOVA

Study arm

ANOVA

Study arm

ANOVA

Study arm

ANOVA

Study arm

Logistic
regression

Average length of stay
during hospitalization
Number of times
hospitalized

Adjusted number of
times hospitalized

Whether a patient was
hospitalized at least
once or not
Time delay before first
hospitalization

ANOVA

Life test and
Kaplan Meier

Time delay before first
hospitalization

Study arm

Time delay before first
hospitalization

Study arm
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Cox
(Proportional
Hazards)
Regression
Cox
Regression

CHAPTER IV
RESULTS
Overview

Congestive Heart Failure is a medical condition characterized by the inability of
the heart to pump enough blood to the rest of the body. Most of its forms are not curable
and when patients are diagnosed with an incurable form of CHF, they are must combat
the disease for the remainder of their life. Available treatments can help these patients
cope with their conditions and live fulfilling lives. These treatments comprise drug
therapies, lifestyle changes, daily weight traction and regular monitoring by a doctor.
The doctor's monitoring and the patient self observation are what define the
management strategy for following the patient. The traditional management method
consists of the patients watching themselves on a daily basis and meeting with their
physician every three to six months. This is the 'Standard or Usual Care'. In the
perspective to assist the patients in their daily self monitoring and aid the doctors thus
providing more effective help to the patients, two relatively new methods have been
suggested: 'Case Management' and "Self Management'. In the current study, in the
'Case Management' strategy, the patient was given a scale which helped them tract their
weight and other important tailored CHF parameters. This scale was connected to a nurse
staffed center via a modem connected to the internet through the phone. The center
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monitored these values and compared them, daily, to a set of normal parameters ranges
defined by the principal physician. In case of a significant change, these nurses informed
the physician for an action or, if necessary, sent the patient to the emergency department.
In the' Self Management' system, the patient was also given a scale which, just like in the
'Case Management' case, helped the patients in the daily self follow up. However here,
the patient was given a 'smart box', connected to the physician' office, which performed
the tasks of the nurse center in the 'Case Management'. If there was a significant change,
it was the automated machine that sent an alert to the physician's office to take action or
told the patient to seek medical help to the nearest emergency department.
Therefore, this study aimed to compare these three managements considering
their cost as well as the benefits to the patients. Particularly, the focus was on evaluating
the feasibility of using Case Management and/or Self Management when compared to the
current standard of care. The main objective was to determine the optimal choice of
follow-up management, for CHF patients, that would benefit the patients without having
a high financial impact.

Description of the sample data
Data used in this study are from a multi-center clinical trial that enrolled a total of 134
participants. These patients were randomized to three arms: 28 patients (21 %) were
as~igned

to the 'Standard Care' (SC) arm, 56 patients (42%) were assigned to the 'Case

Management' (CM) arm and 50 participants (31 %) were assigned to the 'Self
Management' (SM) arm (see Table 4.1).
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The mean age in the clinical trial was 66 with a standard deviation of 13. About
54% ofthe participants were above 65 years old. Most of the participants were female
(59%) and a majority were white (78%). Thirteen percent (13%) of patients were current
smokers, 32% were smokers in the past but had quit at the time of enrollment and 34%
had never smoked. Marital status was taken at the enrollment: 70 enrollees were married
(52%),31 were divorced (23%) and 33 were widowed (25%). Among all participants 48
lived alone (36%). The education level was available for sixty seven participants (50%),
of whom 36 attended and/or graduated from high school (27%) and 29 attended and/or
graduated from college (22%). Patients had different types and characteristics of CHF,
56% had Systolic Heart Failure (SHF), 53% had Diastolic Heart Failure (DHF) and the
majority of them (51 %) had a depressed left ventricular function with a left ventricular
ejection fraction (LVEF) less or equal to 35%. The patients were stratified into class II,
III and IV (43% were class II, 46% were class III and 11 % were class IV). Additionally,
class was divided into two class factors (class II versus class III or IV). The CHF related
medications taken by patients while on the study were available for all participants: 114
patients were on Beta blockers (85%), 77 were on ACE inhibitors (57%) and 47 were on
AR Blockers (35%). The important co-morbidities ofCHF were recorded at the
beginning of the study. The average BMI (Body Mass Index) for the patients enrolled in
the study is 30 with a standard deviation of 11. About half of the patients were obese
(51 %). For the patients for whom the hypertension status was documented, 108 had
hypertension (81 %). Diabetes I was present in only 6% of the patients while Diabetes II
was present in 38% of the patients. Among the patients for whom the

33

---------------------------

hypercholesterolemia status was available, 37 had high cholesterol (28%). The
hyperlipidemia status was also taken: 49 patients were positive (38%) (See Table 4.1)
During the 12 month study, about 17% ofthe patients enrolled were lost to follow
up and 2% died (see Table 4.1).
Table 4.1: Characteristics of the data

Type

Variable
Mean Age (SD)
Age ~ 65
Gender
Male
Ethnicity
White
Black
Hispanic
Marital Status
Demographics
Married
Divorced
Widowed
Lives alone
Education level
High School
College
Smoker
Current
Quit
Never
Systolic
Diastolic
LVEF:s 35%
CHF types
NYHA class
And
Class II
characteristics
Class III
Class IV
NYHA class
Class III or IV
CHF
ACE inhibitors
medications
Beta-blockers
taken
AR Blocker
ACE or ARB

SC (28)
N(%)
68 (14)
20 (71)

eM (56)
N(%)
65 (13)
23 (41)

SM (50)
N(%)
67 (13)
30 (60)

Total (134)
N(%)
66 (13)
73 (54)

10 (36)

22 (39)

23 (46)

55 (41)

24 (86)
3 (11)
0(0)

41 (73)
13 (23)
0(0)

40 (80)
6 (12)
2 (4)

105 (78)
22 (16)
2 (1)

17 (61)
4 (14)
7 (25)
9 (32)

30 (54)
13 (23)
13 (23)
20 (36)

23 (46)
14 (28)
13 (26)
19 (38)

70 (52)
31 (23)
33 (25)
48 (36)

6 (21)
9 (32)

18 (32)
8 (18)

12 (24)
12 (24)

36 (27)
29 (22)

4 (14)
6 (21)
13 (46)
13 (54)
20 (71)
14 (46)

5 (9)
22 (39)
18 (32)
35 (63)
26 (54)
36 (64)

9 (18)
15 (30)
14 (28)
27 (54)
25 (50)
20 (40)

18 (13)
43 (32)
45 (34)
75 (56)
71 (53)
69 (51)

16 (56)
10 (36)
2 (7)

24 (43)
26 (46)
5 (9)

17 (34)
25 (50)
8 (16)

57 (43)
61 (46)
15 (11)

12 (43)
17 (61)
22 (79)
7 (25)
23 (82)

31 (55)
36 (64)
50 (89)
18 (32)
49 (88)

33 (66)
24 (48)
42 (84)
22 (44)
43 (86)

76 (57)
77 (57)
114 (85)
47 (35)
115 (86)
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SC (28)
Type

Variable
Mean BMI (SD)
Obese (BMI~30)
CHF coHypertension
morbidities
Diabetes I
Diabetes II
Hypercholesterol
Hyperlipidemia
Loss to follow up
Death

eM (56)

SM (50)

Total (134)

N(%)

N(%)

N(%)

N(%)

32 (14)
18 (64)
26 (93)
1 (4)
11 (39)
9 (32)
12 (43)
3 (11)
0(0)

31 (11)
30 (54)
45 (80)
6 (11)
21 (38)
21 (38)
16 (29)
12 (22)
2 (4)

·29 (8)
20 (40)
37 (74)
1 (2)
19 (38)
19 (38)
12 (24)
8 (16)
1 (2)

30 (11)
68 (51)
108 (81)
8 (6)
51 (38)
49 (37)
37 (28)
23 (17)
3 (2)

Descriptive statistics: Distribution of the outcome variables of interest
CHF is mostly characterized by the frequent hospitalization of the patients. The
treatments and the management strategies used have one important objective, to reduce
and prevent these hospitalizations. In this study, the three study groups were compared in
hospital free days, total number of in-hospital days during the study period, average
length of stay per hospitalization, number of hospitalizations and having been
hospitalized at least once, and time until first hospitalization. Since some patients died or
were lost to follow up, all the patients do not have the same length in the study. Thus, in
order to put the outcome variable on a comparative level, for each patient, the adjusted
variables corresponding to the response variables were calculated and were also used for
a comparison of the three arms.
Throughout the trial, the 'Standard Care' arm was represented with better
outcomes for all variables (see table 4.2). For example, 24 patients (86%) in this arm had
more than 300 hospital free days compared to 42 (75%) in 'Case Management' and 40
(80%) in 'Self Management'. This finding remained consistent even when using the
adjusted variables. Half of the participants assigned to the 'Standard Care' arm were not
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hospitalized at all during the study and only 4% spent more than 30 days in the hospital
in total. In the 'Case Management' arm, about 5% of the patients spent more than 30 days
in the hospital and the percentage of people in this category from the 'Self Management'
arm was 6%. After adjusting the in-hospital stay variable to consider the loss to follow-up
and the death, the percentages changed slightly. The in-hospital stay of more than 30 days
was about 7% for the 'Standard Care' arm, 7% for the 'Case Management' arm and 8%
for the 'Self Management' arm. At each hospitalization, 39% of the participants in the
'Standard Care' arm stayed for zero to five days on average while only 32% of each of
the other management strategies stayed this long. Only in the 'Case Management' arm,
patients were hospitalized more than five times. In the 'Self Management' group, 24%
were hospitalized between once and five times compared to only 7% in 'Standard Care'
arm. After adjusting for this variable, no patient from the' Self Management' arm was
found to be hospitalized more than five times while about 4% of the patients in the
'Standard care' arm and 9% ofthe patients in the 'Self Management' arm were found in
this category.
Overall, 67% of the participants were hospitalized at least once in the 12 month
study. Stratified by study arms, the percentages of the patients who were hospitalized at
least once were as follow: 57% in the 'Standard Care', 61 % in the 'Case Management'
and 80% in the 'Self Management' arm. (See table 4.2).
In this study, the three arms were also compared considering the cost and the
effect of the management strategies. The fixed and the variable costs as well as
effectiveness were used to evaluate the most cost effective follow up method. The clinical
trial study did not collect data on the cost, thus, a third party data set and expert
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collaboration were used to estimate the needed costs for analysis. The fixed costs
comprised the estimated total expenditure to the physician visits, the nurse training in the
'Case Management' arm' and the 'smart box' in the 'Self management' arm. The variable
costs included home medications, one night hospital stay and nurse daily pay. The
effectiveness in this study was considered to be the number of hospital free days. Since
this variable may be biased by the loss to follow up and death, the effectiveness was
counted as the adjusted number of hospital free days. The fixed effectiveness was
obtained by taking the mean of the variable adjusted hospital free days. In the analysis, it
was considered that a day at home would be valued a one incremental unit. If the patient
spent a day at the hospital, then the effectiveness was' -1' (which means one hospital free
day lost). Death had an incremental value of zero (see table 4.3).

Table 4.2: Distribution of the response variables

Outcome variable
Number of hospital
free days
Adjusted hospital free
days
In-hospital days

Adjusted in-hospital
days
Average length of
stay
Number of
hospitalizations
Adjusted number of
hospitalizations
Hospitalized at least
once

Levels
[1,200]
[201,300]
>300
[201,300]
>300
[1,10]
[11,30]
>30
[1,10]
(10,30]
>30
[1, 5]
(5,10]
>10
[1, 5]
>5
[1,5]
>5
No
Yes

SC
(N=28)
3 (11)
1 (4)
24 (86)
1 (4)
27 (96)
11 (39)
2 (7)
1 (4)
11 (39)
1 (4)
2 (7)
11 (39)
2 (7)
1 (4)
2 (7)
0(0)
1 (4)
1 (4)
12 (43)
16 (57)
37

CM
(N=56)
12 (21)
2 (4)
42 (75)
2 (4)
54 (96)
17 (30)
8 (14)
3 (5)
15 (27)
9 (16)
4 (7)
18 (32)
6 (11)
4 (7)
3 (5)
3 (5)
5 (9)
5 (9)
22 (39)
34 (61)

SM
(N=50)
6 (12)
4 (8)
40 (80)
3 (6)
47 (94)
22 (44)
1 (2)
2 (6)
21 (42)
1 (2)
4 (8)
17 (32)
6 (12)
3 (6)
2 (4)
0(0)
7 (14)
0(0)
10 (20)
40 (80)

p-value
0.4765
0.8057

0.4638

0.3774

0.9939
0.1861
0.0724
0.0482*

Total
(N=134)
21 (16)
7 (5)
106 (79)
6 (4)
128 (96)
50 (37)
11 (8)
7 (5)
47 (35)
11 (8)
10 (7)
46 (34)
14 (10)
8 (5)
7 (5)
3 (2)
13 (10)
6 (4)
44 (33)
90 (67)

In summary, the variable hospital free days was skewed to the left (see figure 4.1)
which represents the fact that a majority had many hospital free days. After adjusting this
variable, it became normally distributed (see figure 4.2). The variable in-hospital days
(figure 4.3) and its adjusted correspondent (figure 4.4) were skewed to the right. Many
patients had few in-hospital days and only few patients had many days in the hospital in
total. The average number of days spent at the hospital per hospitalization was skewed to
the right. This shows that many people had relatively shorter stays. The number of
hospitalizations (figure 4.5) as well as the adjusted number of hospitalizations (figure 4.6)
was also skewed to the right. In the trial, only few patients were hospitalized many times.
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Figure 4.1: Density distribution of the hospital free days for all the participants
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Figure 4.2: Density distribution of the adjusted hospital free days for all the
participants
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Figure 4.3: Density distribution of the in-hospital days for all the participants
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Figure 4.4: Density distribution of the adjusted in-hospital days for all the
participants
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Figure 4.5: Density distribution of the average length of hospital stay for all
participants
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Figure 4.6: Density distribution of the Number of hospitalizations for all
participants
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Inferential statistics: Comparison of the effects of the three CHF management
methods
The main objective of this study was to compare the three management strategies
used in monitoring patients diagnosed by incurable versions of CHF. The three
management strategies are: the 'Standard Care', the 'Case Management' and the 'Self
Management'. These consequences of most interest are hospitalizations, Emergency
Department (ED) visits and increased length of stay during a hospitalization. In this
analysis, these three management strategies were evaluated bases on hospital free days,
total number of in-hospital stays, average length of stay per hospitalization, total number
of all- cause hospitalizations, the proportions ofthe patients who were hospitalized at
least once, and the delay to first hospitalization. In addition, cost effectiveness ratios for
the two experimental arms, which not only considered the effectiveness as hospital free
days but also the cost that implementing them would require was calculated. The
hypothesis was that, in terms of outcomes, the 'Case Management' would be superior or
at worst similar to the 'Self Management' strategy and that both would be superior to the
'Standard Care'. In terms of cost, the hypothesis was that the 'Standard Care' would be
the least expensive, followed by 'Self Management' and that 'Case management would
be the most costly. The ultimate goal of this study was to indicate to patients and their
physician, as well as any financial responsible party involved, the most cost effective
management strategy. The descriptive statistics above suggested some differences in
outcomes; however, it was of great necessity to evaluate the statistical significance of
these differences.
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To compare the hospital free days, the in-hospital days, the average length of stay
and the number of hospitalization, the ANOVA models discussed above were used. The
evaluation of the significance in the proportions of patients hospitalized at least once was
performed using the Logistic Regression above and the comparison of the time delay to
first hospitalization was done by using Kaplan Meier methods and Cox Regression
(Proportional Hazard Regression) techniques. All the statistical tests performed were
two sided with a 0.05 significance level. Also, for continuous variables, the means and
standard deviations were calculated. For the categorical variables, the counts and the
corresponding percentages were presented.
Hospitalfree days comparisons: The average number of hospital free days was different
across study arms. 'Standard Care' had the highest hospital free days (335

± 72),

followed by 'Case management' (298 ± 114) and 'Self Management' had the lowest
number of hospital free days (325 ± 86). The average hospital free days seem to suggest
that 'Case Management' had the worst outcome. However, the F-test of the three group
comparison revealed no statistical difference (p-value=0.1850) (see table 4.4). The pairwise comparisons of this variables also showed that the differences were not statistically
significant (see table 4.5). This result held also for the adjusted hospital free days.
Adjusted hospital free days are the regular hospital free days with a weight representing
the actual number of days the individual spent into the study. For this variable, the three
group difference were not significant (p-value=0.9579, see table 4.4) and the pair-wise

comparisons of the study arms were not significant either (see table 4.5).
In-hospital days comparisons: The variable 'in-hospital days' measured the total number
of days the patient spent in the hospital during the study period of 12 months. The
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'adjusted in-hospital days' are the 'in-hospital days' taking into consideration the loss to
follow up and death. The study analysis results yielded 6 ± 17 in-hospital days in average
for the 'Standard Care', 9 ± 24 in-hospital days for the 'Case Management' and 7 ± 19
in-hospital days for the 'Self Management' . In this study, a hospitalization was measured
as a failure hence, the arm with the least number of in-hospital days, had a better outcome
than the other arms. Thus, considering the mean values, the 'Standard Care' had better
results, followed by 'Self Management' and the worst results were associated with the
'Case Management' arm. These results suggested a difference in 'in-hospital days', to
conclude about its statistical significance, the three groups were first compare
simultaneously and the difference was found not statistically significant (p-value=0.7708,
see table 4.4). The analysis ofthe 'adjusted in-hospital days' led to an analogous
conclusion. The average number (}f days was 7 ± 19 days for' Standard Care' , 25

± 113

days for 'Case Management' and 9 ± 24 days for 'Self Management' . Even though these
numbers show some difference, suggesting that 'Case Management' had the worst
outcomes, the test of differences showed no statistical significance (p-value=0.4493, see
table 4.5). For these two corresponding variables, the pair wise comparisons also showed
no significant differences (see table 4.5). Thus, from this study, it cannot be concluded
that neither 'Self Management' nor 'Case Management' had different 'in-hospital days'
for the CHF.
Length ofstay comparisons: The variable 'Length of stay' measured the average number
of days the patient stayed at the hospital each hospitalization. The average 'length of
stay' was about the same in mean values for 'Standard Care' and 'Case Management': 3

±6 and 3 ±4 respectively. In the 'Self Management' arm, the patients spent an average
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of 4 ± 13 days per hospitalization. These results seemed to suggest that the' Standard
Care' and the 'Case Management' had similar lengths of stays during treatment and 'Self
Management' had a different outcome. However, the test of these differences showed no
statistical difference (p-value=O.6012, see table 4.4). Again there was not enough
evidence from this study to conclude that 'Self Management' or 'Case Management' had
a different outcome than 'Standard Care'.
Number of hospitalizations comparisons: On average, a patient in the 'Case

Management' arm was hospitalized 2 ± 3 times while a patient in the 'Standard care' and
in 'Self Management' arms stayed at the hospital 1 ± 2 times. The difference is of about
one day. The F test comparing the three groups yielded no statistical difference (pvalue=0.4792, see table 4.4). Taking into consideration the loss to follow up and the
death, if all patients had stayed into the study ended alive then a patient in the 'Standard
Care' arm would have been hospitalized 2 ± 4, a patient in the 'Case Management' arm
would have been hospitalized 3 ± 8 times and a patient in the 'Self Management' arm
would have stayed at the hospital 2 ± 3 times. The greatest frequency of hospitalization is
found in the 'Case Management' arm. However, statistically, the differences were not
significant (p-value=0.2644).
Comparison of the proportions ofpatients hospitalized at least once (Comparison of the
risks of hospitalization): The variable considered, in this analysis, measured being

hospitalized at least once in the study. The difference in proportions was not statistically
significant (p-value=O.6986, see table 4.4). The objective of this part of analysis was to
look at the odds of being hospitalization (or the odds of hospitalization) in the 'Case
Management' arm or the' Self Management' arm compared to the' Standard Care' arm.
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The odds of being hospitalized for 'Case Management' versus 'Standard Care' were
1.000 (95% confidence interval = (0.403, 2.483)). The risk of hospitalization was nonsignificantly was about the same in the 'Standard Care' arm and in the 'Case
management'. The odds ratio estimate for being hospitalized for 'Self Management'
versus 'Standard Care' were 0.738 (95% confidence interval = (0.292, 1.867)). The Self
Management strategy reduced the risk of hospitalization for about 30%, but was not
significant. The odds ratio estimate for being hospitalized for 'Case Management' versus
'Self Management' were 1.355 (95% confidence interval = (0.63, 2.911)). The 'Case
Management' method increased the risk of hospitalization by a little bit over 30% (see
table 4.5), but not significantly.
Comparison of the times to first hospitalization: A better 'time delay' strategy would

mean a better outcome in terms of risk of hospitalization. The Kaplan Meier curve
(Figure 4.7) showed a difference in time delay in the three management systems during
the study illustrating the 'Standard Care' to have a longer delay. On average, the time
delay to first hospitalization was of 139 ± 118 in the 'Standard Care' patients, 98 ± 100 in
the 'Case Management' group and about 139 ± 104 in the 'Self Management' group.
However, the log-rank testing equality over group revealed that the three arms did not
have statistically significant different time delays to first hospitalization (p-value=0.4343,
see table 4.4). Further analysis consisted of evaluating the hazards of hospitalizations in
pair-wise comparisons. The hazard ratio estimate of 'Case Management' compared to
'Standard Care' was of 1.462 (95% confidence interval = (0.813, 2.631)) and the hazard
ratio estimate of 'Self Management' in comparison to the 'Standard Care' was of 1.427
(95% confidence interval = (0.686,2.266)). This showed that the patients in the 'Case
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Management' or in the 'Self Management' groups had a non-significant 40% chance
increase of being hospitalized earlier, than their peers in the 'Standard Care' group. The
hazard ratio of 'Case Management' versus 'Self Management' was found to be 1.173
(95% confidence interval = (0.733, 1.877)) which showed that the risk of an earlier
hospitalization was about 17% higher in the 'Case Management arm than in the 'Self
Management' arm in a non-significant manner (Table 4.5).
Table 4.3: Study arms comparisons
Type of
analysis

Group
means
compansons

Group
proportions
comparisons
Time to
failure
comparisons

Outcome
variable
HFD
A*HFD
IHD
A*IHD
ALOS
H
A*H
Hosp.** at
least once

Value
format

Mean
(std)

N(%)

SC
(N=28)
335 (72)
358 (19)
6 (17)
7 (19)
3 (6)
1 (2)
2 (4)

CM
(n=56)
298 (114)
357 (28)
9 (24)
25 (113)
3 (4)
2 (3)
3 (8)

SM
(n=50)
325 (86)
356 (24)
7 (19)
9 (24)
4 (13)
1 (2)
2 (3)

p-value
0.1850
0.9579
0.7708
0.4493
0.6012
0.4792
0.2644

16 (57)

34 (61)

40 (80)

0.6986

Time to
98 (100) 139 (104) 0.4343
1st
Mean
139 (118)
(std)
hospital
encounter
HFD = Hospital Free days, IHD = In-Hospital Days, ALOS = Average Length Of Stay,
H=Number of hospitalizations, *A=Adjusted, ** Hosp. = Patients hospitalized at least
once
Table 4.4: Post-hocs study arms comparisons
Type of
ana!ysis

Outcome
variable
HFD
A*HFD
Group
IHD
means
A*IHD
comparisons
ALOS
H
A*H

Test
measure

p-value

CMvs. SC
0.1
0.8678
0.5101
0.3090
0.9857
0.4140
0.2796
47

SMvs. SC
0.6449
0.7709
0.8334
0.9222
0.4389
0.8852
0.8263

CMvs.
SM
0.1608
0.8766
0.5969
0.2750
0.3590
0.2521
0.1216

Type of
Outcome Test
CMvs.
analysis
variable
measure CMvs. SC SM vs. SC SM
Hosp.** at
OR
1.000
0.738
1.355
Group
proportions least once (95% CI) (0040, 2048) (0.29, 1.87) (0.63,2.91)
comparisons
Time to
Time to
HR
10462
1.247
1.173
failure
1st
(95% CI) (0.81,2.63) (0.67,2.27) (0.73, 1.88)
comparisons
hospital
encounter
OR = Unadjusted Odds Ratio, HR = Unadjusted Hazard RatIO, CI = Confidence Interval
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CHAPTER V
DISCUSSION

Overview

In the current study, clinical trial data was used to analyze seven primary outcome
measures (traditionally used) to determine whether differences exist between three
management strategies 'Standard Care', 'Case Management' and 'Self Management'
used in monitoring Congestive Heart Failure (CHF) patients. Traditional statistical
analyses were used to test for differences among the three groups of individuals. The
seven outcome measures evaluated in the current study were: (1) hospital free days, (2) in
hospital days, (3) average length of stay per hospitalization, (4) number of
hospitalizations, (5) proportions of patients hospitalized at least once during the study
period and (6) time until the first hospitalization. These variables were examined to
answer the following research questions:
1) Does the number of hospital free days differ in the three strategies?
2) Does the number of in hospital days differ in the three strategies?
3) Does the average length of hospital stay differ in the three strategies?
4) Does the management strategy have an effect on hospitalization usage?
5) Is the time until the first hospitalization the same in the three strategies?
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As a result, primary and secondary research questions were addressed using the in
trial clinical data.

Description of findings
In this clinical trial, the 'Case Management' and the 'Self Management' arms had
more patients who experienced bad outcomes for almost all outcome variables
considered, when compared to the traditional 'Standard Care' arm. Although the 'Case
Management' arm did have patients who experienced better outcomes on some variables
when compared to the 'Self Management' (see table 4.2). However, differences observed
were not found to be statistically significant. Therefore, the results from the current study
did not establish if one management strategy had significantly better outcomes when
compared to the other two strategies. As result, the current study cannot advocate one
management strategy for monitoring CHF patients. That is, the test statistics calculated
revealed no significant difference between the arms in terms of hospital free days, inhospital days, length of stay, number of hospitalizations, risk of hospitalization
(proportion of patients hospitalized at least once) and time delay to first hospitalization.
The pair-wise comparisons also did not indicate any statistical differences. The results
obtained in this study were consistent with published studies in the literature. Previous
researchers have found that there were no difference in health outcomes between patients
who were followed with the usual care and those who were monitored with special
disease managements [22,23]. In a randomized, controlled clinical trial study comparing
the usual care to the enhancement of care with a nurse management, DeBusk et al [22]
found that the rate of first re-hospitalization and all cause re-hospitalizations were similar
in both study groups. Also, from a clinical trial where participants were randomized to
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either a control group or a case management group, Laramee et al [23] reported that the
90-day readmission rates were the same in both groups. The disease management groups
(intervention group) in these two reports correspond directly to the 'Case Management'
group in the current study. The current study concluded that the 'Case Management'
group and the 'Standard Care' group did not significantly differ based on hospital usage
(hospital free days, in-hospital days, number of hospitalizations, time to first
hospitalization, and length of hospital stay). Therefore, the findings in the current study
coincide with those found in DeBusk et al and Laramee et al.
Similar to the published literature, in which there are observed disagreement, the
current study's results differ from some published reports. Many results and conclusions
studying case management strategies have been controversial and in disagreement. Some
analyses have reported a positive effect for some outcomes [19,20], while being
associated with negative effects [21] for others. Smith and colleagues [19] found that the
assignment of a registered nurse as a disease manager resulted in improvements in the
qualitative outcome self-reported improvement in health at 6-months and 12-months after
discharge in a community dwelling population. In agreement with Smith et aI, Sisk et al
[20] showed that a nurse management improved functioning and lowered hospitalizations
in a diversified population in Harlem, NY. In contrast, Weinbergeret al [21]
demonstrated that in a population of discharged veterans from nine Veterans Affairs
Medical Centers, though a close follow up by a nurse increased patient satisfaction, the
rate of hospitalization was rather increased.
To this investigator knowledge, the current study is novel in reporting the
comparison of the 'smart box' management approach to usual care and to the nurse
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management approach. Therefore, this thesis is pushing knowledge forward and filling a
gap in the knowledge base concerning management of CHF patients.

Limitation of the study
The current study did not consider the cost of implementing the' Self
Management' or the 'Case Management' strategies in comparison to the standard of care.
A cost effectiveness analysis would provide a complete comparison of the three
management methods by providing the incremental cost effectiveness when using either
of the newer management strategies in comparison to using the standard strategy. Also,
the analysis considered all cause hospital usage; a more sophisticated analysis may wish
to adjust the cause of the hospital usage and compare the three methods with respect to
these causes.

Implications
CHF is a chronic unfortunate condition that diagnosed patients will have to
manage for the rest of their lives. Patients should change their life styles, comply with
medications and adhere to daily self -monitoring. To avoid a preventable deterioration of
their condition, it is imperative to evaluate all management strategies that can assist them
with their disease. It is for this reason the current comparison was performed.
The new management strategies bring an additional interconnection between the
physician and the patient to usual care that can be of great importance. With this bridge,
the patients are encouraged and acquire effective means to self-follow their daily changes
and earlier detection of any significant deterioration in their condition which can be taken
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care of earlier. This may result in a decrease in hospital usage and in an overall better
health status for CHF patients.
In this study, comparing the management strategies 'Usual Care', 'Case
Management', and Self Management' did not yield any statistical significant differences
in terms of health outcomes measured. Nevertheless, the input of a management strategy
is of necessity because of its characteristics to bring the patients closer to their
physicians. Even though the health outcomes were found to be similar, prior published
reports have reported patient satisfaction and quality of life in association to the
implementation of management programs [18,21]. In the current study, the 'Self
Management' strategy was found to be comparable to the 'Case Management' strategy
for which patient satisfaction has been proven [18, 21]. Hence, with a cost comparison of
the management programs, either 'Self Management' or 'Case Management' may be
found to be financially feasible and very beneficial to the patients.

Further research
Further research regarding the management of CHF will warrant a deeper analysis
of these management strategies. To accomplish this, all the sets of the clinical trial
records should be analyzed and the management arms should be compared adjusting for
important characteristics of the CHF condition. Moreover, a cost effectiveness analysis
should be conducted in order to ensure a management choice that considers both the costs
incurred by health care purchasers (i.e., Humana, United, Aetna) as well was the medical
effectiveness for the patient. Also, a qualitative research design could be considered with
the patients participating during the trial in qualitative surveys, focus groups or in one-on-
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one interviews. This not only would allow participants to provide an input regarding their
satisfaction about the strategy they were assigned to but also it would help in determining
the optimal choice of management strategy for them using a more comprehensive
approach. In addition, a cost effectiveness analysis should be undertaken to estimate the
incremental cost effectiveness of managing congestive heart failure patients with either
Self Management or Case Management in comparison to the standard care.

Summary and conclusions
Patients diagnosed with Congestive Heart Failure will be under a physician care
for the remainder of their life. It is of great importance that the strategy used to manage
these patients maximizes their health care outcome (days out of the hospital, patient
satisfaction and quality oflife) in an effective manner. The purpose of this study was to
determine which of the three management strategies (,Standard care', 'Case
Management' and 'Self Management') would provide better health outcome. 'Case
Management' has been proposed to enhance patient self-daily monitoring, encourage
patient compliance to medication and create a professional and knowledgeable
connection between the patient and the physician, in order to detect earlier any sign of
CHF condition deterioration. 'Self Management' was introduced to achieve the same
benefits as the 'Case Management' while eliminating the cost of an intermediate nurse.
Thus, the particular objective of the current study was to analyze whether 'Case
Management' or 'Self Management' was beneficial when compared to 'Standard Care',
and whether 'Self Management' may be comparable to 'Case Management'. This goal
was realized by evaluating the differences in these strategies and testing these differences
for statistical significance. In overall, the study found no evidence from this clinical trial
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that either 'Case Management' or 'Self Management' have different outcomes when
compared to 'Standard Care'; in terms of hospital free days, average length of hospital
stay, number of hospitalizations, risk of hospitalization and time delay to first
hospitalization.
Nevertheless, considering the fact that an enhanced follow up strategy constitutes
a bridge between the patients and the doctors, a management program with a nurse or
with a 'smart box' may be a useful tool that warrants consideration. A cost effectiveness
comparison of the two approaches may provide a financially acceptable and reasonable
choice leading to better patient health outcomes. This study encountered limitations due
to the complete lack of cost comparison. The comparison of the management methods
was performed considering patient health outcomes. Despite these limitations, this
analysis provided important and additional information to address the existing
controversy of the effect of disease management programs on CHF health outcomes. A
more in depth analysis considering all the subsets of this clinical trial data would lead to a
better understanding of the complete effect of these management strategies. Further data
collection through interviews and surveys of all the patients alive who participated to the
clinical trial would assist as well by providing a better individual choice of an optimal
management choice.
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